E10030: Phase I started

Ophthotech began an open-label, single-ascending dose, U.S. Phase I (OPH 1000) trial to evaluate intravitreal E10030 plus Lucentis ranibizumab (0.5 mg/eye) in up to 36 patients. Lucentis is marketed ...